Fighting the most prevalent mosquito-borne viral disease.

VIS513 is a humanized monoclonal antibody that is being evaluated for the treatment of Dengue, which causes clinically significant disease in up to 100 million people each year worldwide. Dengue may include severe complications leading to death. There are no approved antiviral therapies for dengue.

VIS513 has been shown to be a highly potent inhibitor of all four types of dengue viruses, both in vitro and in preclinical animal models. We have licensed VIS513 to the Serum Institute of India Pvt. Ltd (SIIPL) for development and commercialization. SIIPL is currently conducting a phase 2 trial of VIS513.